Press release
Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel
BILLERICA, MA, April 14, 2023 - At the 33rd European Congress of Clinical Microbiology & Infectious Diseases, Bruker Corporation (Nasdaq: BRKR) announces its latest innovations for user-friendly, best-in-class diagnostic solutions for routine clinical microbiology and infection diagnostics laboratories.• MBT Mycobacteria IVD Kit optimizes sample preparation and comprehensive library of MBT HT Mycobacteria IVD Module
• MBT HT Filamentous Fungi IVD Module incorporates extensive fungal library with easy and effective sample preparation (MyT)
• New MBT Compass HT IVD software significantly increases speed for microbial identification, with unique automated self-tuning
• New LiquidArray® Gastrointestinal PCR Panel detects 26 pathogens causing gastroenteritis, covering bacteria, viruses, parasites and associated toxins
1. Bruker introduces fast next-generation MALDI Biotyper® IVD Software
Microbial identification faster than ever: The MBT Compass HT IVD software provides a high sample throughput for microbial identification with time-to-result of ~5 minutes for 96 sample spots. Because of a fast sample target exchange, the MBT system can now analyse up to 600 samples per hour, while covering over 4,600 species in the reference library.
Microbial identification with optimal performance: The new IDealTune™, part of the MBT Compass HT IVD software, provides fully automated tuning of MALDI-TOF parameters within a sample run, delivering consistent data quality without user intervention. This seamless and effortless approach further increases performance, reproducibility, and up-time of the system.
2. Optimizing sample preparation for mycobacteria
As mycobacteria are challenging species in microbiology, an optimized sample preparation protocol is essential for robust results. The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media. The inactivation method for safe sample handling does not require boiling but convenient incubation of the mycobacteria with an inactivation reagent at room temperature.
Dr. Arthur Pranada, Head of the Microbiology Division at MVZ Dr. Eberhard & Partner in Dortmund, stated: "During the last years the number of clinical samples with nontuberculous mycobacteria has increased, and reliable identification is important for an assessment of the clinical significance. The MBT Mycobacteria IVD Kit further simplifies the workflow for identification of nontuberculous mycobacteria by MALDI-TOF MS and reduces hands-on time. During the evaluation in our laboratory more than 96% of mycobacteria from solid and liquid media could be identified at a high-confidence level."
Identifying challenging filamentous fungi
Identifying molds and multicellular fungi remains one of the most complex aspects of microbiology, because of varying culture conditions and colony morphology. The new MBT HT Filamentous Fungi IVD Module comes with an easy, yet powerful Mycelium Transfer (MyT) sample preparation procedure which together with a comprehensive reference library offers high identification success rates.
3. New LiquidArray® Gastrointestinal PCR Assay for Broad Syndromic Testing
Rapid culture-free pathogen identification: Bruker's LiquidArray® technology offers rapid, multiplexed PCR pathogen detection for ease of implementation. Launched on the high-precision FluoroCycler® XT thermocycler, LiquidArray® combines innovative probe and thermocycling technologies with results-at-a-glance visualization for the simultaneous analysis of multiple targets from a single sample. The integrated FluoroSoftware® XT-IVD generates easy-to-interpret results, accelerating clinical decisions. The new LiquidArray® Gastrointestinal is a syndromic panel that enables the simultaneous detection of up to 26 pathogens causing gastroenteritis. LiquidArray® Gastrointestinal is validated on the GenoXtract® fleXT which streamlines extraction and PCR. This provides high-throughput clinical laboratories with a fully integrated workflow from sample to result.
Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, commented: "With the introduction of our new IVD workflows, kits, software and reference libraries for mycobacteria and fungi, we further expand the applications of our established MALDI Biotyper® platform. This creates additional value for all current and future customers. The new LiquidArray® Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run."
Investor Contact
Justin Ward
Senior Director Investor Relations and Corporate Development
+1 (978) 663-3660, ext. 1479
investor.relations@bruker.com
Customer & media contact
Philip Perry
Bruker Microbiology & Infection Diagnostics
+49-172-313-7216
Philip.Perry@bruker.com
About the Bruker MALDI Biotyper® (MBT) platform
The MBT enables molecular identification of bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using a molecular approach based on proteomic fingerprinting by high-throughput MALDI-TOF MS. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. In many international laboratories, the MBT has replaced classical biochemical testing for bacterial identification due to its accuracy, speed, extensive species coverage, ease of use, minimal sample preparation and cost-effectiveness. MBT products are available in a research use only (RUO) version, as general purpose (GP) version, as the U.S. FDA-cleared MBT CA System, or in an IVD-CE version. The MBT also has IVD medical device registrations in numerous other countries.
About the Bruker LiquidArray® technology
The innovative LiquidArray® technology optimizes asymmetrical multiplex PCR for creating excess single-stranded amplicons with detection by Lights-On/-Off probes that contain a quencher (Lights-Off) or both fluorophore and quencher (Lights-On). If both probes are hybridized in proximity on the amplicon, the quencher of the Lights-Off probe eliminates the fluorescence emitted by the Lights-On probe. During melting curve analysis, Lights-On/-Off probes detach from the amplicon at specific temperatures. In the unbound state, Lights-On probes cannot emit, and as fluorescence is either emitted or suppressed, specific fluorescence signatures are generated by the unique FluoroCycler® XT thermocycler for the LiquidArray® multiplex PCR technology. The LiquidArray® technology supports multiplexed assays where a large number of targets is analyzed simultaneously from single samples. For example, the LiquidArray®-powered, WHO-endorsed FluoroType® MTDBR VER 2.0 assay detects more than 500 genotypes by the combined analysis of up to 45 different mutations in mycobacteria.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel here
News-ID: 3019479 • Views: …
More Releases from The Scott Partnership
Linkam showcases new stage innovation at M&M 2025
Market leader in temperature and environmental-controlled microscopy, Linkam Scientific Instruments, will be presenting a range of stages at this year's Microscopy & Microanalysis (M&M) 2025. The showcase will include its cryo portfolio, amongst other new developments, at booth #1439, M&M Salt Lake City, July 27-31.
15 July 2025: Linkam Scientific Instruments is showcasing a range of microscopy stages and instrumentation at this year's M&M conference, including its core stages, new products,…
SGD Pharma advances sustainable manufacturing and supply chain innovation at DCA …
Paris La Défense, FRANCE - 19th March 2025: SGD Pharma, a global market leader in pharmaceutical glass primary packaging solutions, leads the charge towards greater sustainability and innovation by highlighting its multi-million investments into the next-generation of glass manufacturing and commitment to strengthening pharma supply chains in the US and beyond. DCAT Week takes place between 17th-20th March 2025 and is one of the most influential gatherings for pharmaceutical and…
N4 Pharma announces collaboration with SRI to target and treat cells in the huma …
April 25th, 2024: N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI, an independent nonprofit research institute based in Silicon Valley, California, to combine Nuvec with SRI's proprietary FOX Three Molecular Guidance System™ (MGS) with the aim of co-marketing the combined technology. The…
N4 Pharma's novel delivery systems, Nuvec® and LipTide®, advance towards comme …
27th February 2024: N4 Pharma PLC (AIM: N4P), the pre-clinical stage specialist pharmaceutical company, recently acquired a controlling interest in Nanogenics Limited. Nanogenics has developed a lipid and peptide-based delivery system, LipTide®, which it is using in the formulation of a novel siRNA product - ECP105 - targeting an unmet clinical need in the ophthalmology market.
Alongside its ongoing pre-clinical research into Nuvec® - N4 Pharma's unique novel silica nanoparticle…
More Releases for MBT
MBT Marketing Recognized as 2024 Premier Partner in Google Partners Program
Portland, Oregon- MBT Marketing, a leading multi-location marketing agency established in 2004, proudly announces its recognition as a 2024 Premier Partner in the Google Partners program, reaffirming the company's dedication to excellence in digital marketing.
In February, Google celebrated the achievements of top-performing digital marketing partners worldwide by awarding Premier Partner status. MBT Marketing has secured its place among the elite tier of Google Partners participants, ranking within the top 3%…
2-Mercaptobenzothiazole (MBT) Market Latest Report: Global Industry Insights, Co …
2-Mercaptobenzothiazole (MBT) is an industrial chemical that is used principally in the manufacture of rubber.
We aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Case numbers are resurging in parts of the world where the COVID-19 pandemic was waning, falling in places…
(Post-pandemic Era) MBT Reinforcing Couple Market 2021 | Detailed Report
The MBT Reinforcing Couple research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information about the MBT…
Investgiation for Investors in shares of Mobile TeleSystems (NYSE: MBT) over pot …
Certain directors of Mobile TeleSystems (NYSE: MBT) are under investigation concerning potential breaches of fiduciary duties.
Investors who are current long term investors in Mobile TeleSystems (NYSE: MBT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in NYSE: MBT stocks follows a lawsuit filed against Mobile TeleSystems over alleged securities laws violations. The…
Worldwide Markets for 2-Mercaptobenzothiazole (MBT) and Extensive Market Forecas …
Albany, New York, February 22, 2017: Market Research Hub has recently announced the addition of a new report to it broad database titled as “Global 2-Mercaptobenzothiazole (MBT) Market Outlook 2016-2021”. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of 2-Mercaptobenzothiazole (MBT) industry has been provided.
Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=979267
2-Mercaptobenzothiazole,…
Model-based testing (MBT) integrating Sparx® Enterprise Architect with HP ALM/Q …
Kaiserslautern, 26 February 2013
For the successful delivery of e-business or complex ERP projects, the discipline and methodology of BPM is crucial for managing business process requirements. Such requirements are gathered from the business in a project's blueprinting phase by creating process models on a business activity level with business process analysis (BPA) tools. Because of the complexity of supporting business processes through and integrating them into applications, user acceptance, integration…